Highest-materiality recent filing
Sight Sciences Q1 revenue up 13% to $19.7M; raises FY 2026 guidance; Alcon damages $55.4M
Q1 revenue $19.7M (+13% YoY); net loss $13.0M ($0.24 loss per share) vs $14.2M loss in prior year.
Sight Sciences wins patent case vs Alcon; awarded $55.4M damages + ongoing royalty
Final judgment in Sight Sciences' patent infringement case against Alcon for Hydrus Microstent.
Order upholds jury finding that Alcon willfully infringed three Sight Sciences patents.
Sight Sciences Q4 revenue $20.4M (+7% YoY); guides 2026 revenue $82-88M
Q4 2025 revenue $20.4M (+7% YoY); Interventional Glaucoma $19.7M (+5% YoY); Dry Eye $0.7M vs $0.3M.
Sight Sciences reports Q4 2025 revenue up 7% YoY; FY 2025 revenue down 3% YoY
Q4 2025 total revenue $20.3M-$20.4M, +7% vs Q4 2024; Surgical Glaucoma +5%, Dry Eye +130%.
Sight Sciences Q3 revenue $19.9M, raises FY25 guidance; promotes COO and CFO
Surgical Glaucoma revenue $19.7M (+6% YoY); Dry Eye revenue $0.2M (-88%) as company focuses on reimbursed access.
Sight Sciences gets Medicare pricing for TearCare from Novitas and FCSO; $1,141.59 fee
Two MACs set jurisdiction-wide pricing for CPT 0563T (TearCare) at $1,141.59, effective Jan 1, 2025.
Sight Sciences extends interest-only period to Feb 2027, ups Tranche 3 to $25M
Interest-only period extended six months to February 1, 2027.
Sight Sciences cuts 20% workforce; CCO departs; reaffirms FY revenue guidance
Reduces headcount by 43 (~20% of global workforce); expects cash restructuring charge of $2.7M-$3.0M in Q3 2025.
Sight Sciences Q2 2025 revenue $19.6M (-8% YoY), raises FY25 revenue guidance to $72-76M
Net loss $11.9M ($0.23 loss per share) vs $12.3M loss in prior year.
As previously disclosed, on April 21, 2025, the Board of Directors (the “Board”) of Sight Sciences, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Gerhard F. Burbach to the Board.
Max materiality 0.80 · Median 0.72 · Most common event earnings